Century Therapeutics, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Century Therapeutics, Inc. (IPSC) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of -$109.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-08-12
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-06-30 was -$109.00K.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-03-31 was -$615.00K.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-09-30 was -$19.00K, a 101.77% decline year-over-year.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-06-30 was -$222.00K.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2025 was -$294.00K, a 292.16% decline from fiscal 2024.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was $153.00K, a 94.12% decline from fiscal 2023.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was $2.60M.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was -$1.79M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$109.00K 10-Q · filed 2026-08-12 | -$724.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$615.00K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | -$294.00K 10-K · filed 2026-03-12 | |||
| 2025-09-30 | -$19.00K 10-Q · filed 2025-11-13 | -$241.00K derived: sum of 2 quarters · filed 2026-08-12 | -$260.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$222.00K 10-Q · filed 2026-08-12 | -$241.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$19.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $153.00K 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $1.07M 10-Q · filed 2025-11-13 | $973.00K derived: sum of 2 quarters · filed 2025-11-13 | $622.00K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$102.00K 10-Q · filed 2025-11-13 | -$453.00K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | -$351.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $2.60M 10-K · filed 2025-03-19 | |||
| 2023-09-30 | -$95.00K 10-Q · filed 2024-11-05 | -$36.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.16M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $59.00K 10-Q · filed 2024-11-05 | $1.25M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $1.20M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | -$1.79M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$165.00K 10-Q · filed 2023-11-09 | -$945.00K derived: sum of 2 quarters · filed 2023-11-09 | -$2.93M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$780.00K 10-Q · filed 2023-11-09 | -$2.77M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$1.99M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |